Cardiotoxicity Screening Market Size, Share, and Trends 2025 to 2034

The global cardiotoxicity screening market size is calculated at USD 3.17 billion in 2025 and is forecasted to reach around USD 8.46 billion by 2034, accelerating at a CAGR of 11.54% from 2025 to 2034. The North America market size surpassed USD 1.25 billion in 2024 and is expanding at a CAGR of 11.64% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

Last Updated : August 2025  |  Report Code : 6624  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cardiotoxicity Screening Market 

5.1. COVID-19 Landscape: Cardiotoxicity Screening Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cardiotoxicity Screening Market, By Assay/Test Type

8.1. Cardiotoxicity Screening Market Revenue and Volume Forecast, by Assay/Test Type

8.1.1. hERG (Kv11.1) Binding and Patch-Clamp Assays

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Automated Patch Clamp (APC)

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Multi-Electrode Array (MEA) with iPSC-Cardiomyocytes

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Calcium-Flux and Optical Electrophysiology Assays

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. In vivo Telemetry/Conscious ECG Studies (rodent, dog, non-rodent)

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. In Silico Predictive Modeling and QSAR/CiPA Workflows

8.1.6.1. Market Revenue and Volume Forecast

Chapter 9. Global Cardiotoxicity Screening Market, By Modality/Approach

9.1. Cardiotoxicity Screening Market Revenue and Volume Forecast, by Modality/Approach

9.1.1. In Vitro (cell and tissue-based)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. In Vivo (animal telemetry, ECG)

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. In Silico/Computational (simulation, PBPK-QT models)      

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Cardiotoxicity Screening Market, By Product and Service Type

10.1. Cardiotoxicity Screening Market Revenue and Volume Forecast, by Product and Service Type

10.1.1. Assay Kits, Reagents and Ready-to-use Cells (iPSC-cardiomyocytes, dyes, media)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Instrumentation and Platforms (MEA systems, APC rigs, patch amplifiers)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Contract Testing Services/CRO Screening Programs

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Software and Predictive Analytics (QTc algorithms, pro-arrhythmia AI)

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Consulting, Validation, and Regulatory Support

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. Global Cardiotoxicity Screening Market, By End User

11.1. Cardiotoxicity Screening Market Revenue and Volume Forecast, by End User

11.1.1. Pharmaceutical and Biotechnology Companies (in-house screening)

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. CROs/Safety and Toxicology Service Providers

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Academic and Research Institutes

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Regulatory Bodies and Translational Consortia

11.1.4.1. Market Revenue and Volume Forecast

11.1.5. Instrument and Reagent Suppliers (internal R&D use)

11.1.5.1. Market Revenue and Volume Forecast

Chapter 12. Global Cardiotoxicity Screening Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.1.2. Market Revenue and Volume Forecast, by Modality/Approach

12.1.3. Market Revenue and Volume Forecast, by Product and Service Type

12.1.4. Market Revenue and Volume Forecast, by End User

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.1.5.2. Market Revenue and Volume Forecast, by Modality/Approach

12.1.5.3. Market Revenue and Volume Forecast, by Product and Service Type

12.1.5.4. Market Revenue and Volume Forecast, by End User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.1.6.2. Market Revenue and Volume Forecast, by Modality/Approach

12.1.6.3. Market Revenue and Volume Forecast, by Product and Service Type

12.1.6.4. Market Revenue and Volume Forecast, by End User

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.2.2. Market Revenue and Volume Forecast, by Modality/Approach

12.2.3. Market Revenue and Volume Forecast, by Product and Service Type

12.2.4. Market Revenue and Volume Forecast, by End User

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.2.5.2. Market Revenue and Volume Forecast, by Modality/Approach

12.2.5.3. Market Revenue and Volume Forecast, by Product and Service Type

12.2.5.4. Market Revenue and Volume Forecast, by End User

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.2.6.2. Market Revenue and Volume Forecast, by Modality/Approach

12.2.6.3. Market Revenue and Volume Forecast, by Product and Service Type

12.2.6.4. Market Revenue and Volume Forecast, by End User

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.2.7.2. Market Revenue and Volume Forecast, by Modality/Approach

12.2.7.3. Market Revenue and Volume Forecast, by Product and Service Type

12.2.7.4. Market Revenue and Volume Forecast, by End User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.2.8.2. Market Revenue and Volume Forecast, by Modality/Approach

12.2.8.3. Market Revenue and Volume Forecast, by Product and Service Type

12.2.8.4. Market Revenue and Volume Forecast, by End User

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.3.2. Market Revenue and Volume Forecast, by Modality/Approach

12.3.3. Market Revenue and Volume Forecast, by Product and Service Type

12.3.4. Market Revenue and Volume Forecast, by End User

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.3.5.2. Market Revenue and Volume Forecast, by Modality/Approach

12.3.5.3. Market Revenue and Volume Forecast, by Product and Service Type

12.3.5.4. Market Revenue and Volume Forecast, by End User

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.3.6.2. Market Revenue and Volume Forecast, by Modality/Approach

12.3.6.3. Market Revenue and Volume Forecast, by Product and Service Type

12.3.6.4. Market Revenue and Volume Forecast, by End User

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.3.7.2. Market Revenue and Volume Forecast, by Modality/Approach

12.3.7.3. Market Revenue and Volume Forecast, by Product and Service Type

12.3.7.4. Market Revenue and Volume Forecast, by End User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.3.8.2. Market Revenue and Volume Forecast, by Modality/Approach

12.3.8.3. Market Revenue and Volume Forecast, by Product and Service Type

12.3.8.4. Market Revenue and Volume Forecast, by End User

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.4.2. Market Revenue and Volume Forecast, by Modality/Approach

12.4.3. Market Revenue and Volume Forecast, by Product and Service Type

12.4.4. Market Revenue and Volume Forecast, by End User

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.4.5.2. Market Revenue and Volume Forecast, by Modality/Approach

12.4.5.3. Market Revenue and Volume Forecast, by Product and Service Type

12.4.5.4. Market Revenue and Volume Forecast, by End User

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.4.6.2. Market Revenue and Volume Forecast, by Modality/Approach

12.4.6.3. Market Revenue and Volume Forecast, by Product and Service Type

12.4.6.4. Market Revenue and Volume Forecast, by End User

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.4.7.2. Market Revenue and Volume Forecast, by Modality/Approach

12.4.7.3. Market Revenue and Volume Forecast, by Product and Service Type

12.4.7.4. Market Revenue and Volume Forecast, by End User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.4.8.2. Market Revenue and Volume Forecast, by Modality/Approach

12.4.8.3. Market Revenue and Volume Forecast, by Product and Service Type

12.4.8.4. Market Revenue and Volume Forecast, by End User

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.5.2. Market Revenue and Volume Forecast, by Modality/Approach

12.5.3. Market Revenue and Volume Forecast, by Product and Service Type

12.5.4. Market Revenue and Volume Forecast, by End User

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.5.5.2. Market Revenue and Volume Forecast, by Modality/Approach

12.5.5.3. Market Revenue and Volume Forecast, by Product and Service Type

12.5.5.4. Market Revenue and Volume Forecast, by End User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Assay/Test Type

12.5.6.2. Market Revenue and Volume Forecast, by Modality/Approach

12.5.6.3. Market Revenue and Volume Forecast, by Product and Service Type

12.5.6.4. Market Revenue and Volume Forecast, by End User

Chapter 13. Company Profiles

13.1. Eurofins Scientific

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Certara

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Sophion Bioscience

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Axol Bioscience,

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Thermo Fisher Scientific,

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Multi-Channel Systems (MCS),

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Nanion Technologies,

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Sophion Bioscience

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Evotec

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. WuXi AppTec

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The cardiotoxicity screening market size is expected to increase from USD 2.84 billion in 2024 to USD 8.46 billion by 2034.

The cardiotoxicity screening market is expected to grow at a compound annual growth rate (CAGR) of around 11.54% from 2025 to 2034.

The major players in the cardiotoxicity screening market include Charles River Laboratories, Labcorp/Covance, Eurofins Scientific, WuXi AppTec, Evotec, ICON plc, Certara, Simulations Plus, Axion BioSystems, Multi-Channel Systems (MCS), Nanion Technologies, Sophion Bioscience, Molecular Devices/Danaher group, Fujifilm-CDI (Cellular Dynamics International), Ncardia (formerly Axiogenesis), Axol Bioscience, Thermo Fisher Scientific, PerkinElmer, and Charles River/HESI/CiPA collaborators

The driving factors of the cardiotoxicity screening market are the increased demand for effective and precise cardiotoxicity screening methods is driving the global market

North America region will lead the global cardiotoxicity screening market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client